An Eatontown-based developer of medical cellular technologies Wednesday announced it has a deal in place to develop cancer-fighting drug delivery methods.
American CryoStem Corporation said in a news release that it has initial agreements with UHV Techologies Inc.’s nanoRANCH division to work on drugs that focus on cancer treatments that utilize adult stem cells.
"We are noticing a sharp increase in demand for our cutting-edge clinically prepared cells and ancillary products for use in scientific development." Anthony Dudzinski, American CryoStem’s chief operating officer, said in the release.
The collaboration will use American CryoStem’s ATCELL products.
"Accurate targeting of pharmaceuticals is a continuing hurdle in drug delivery, and particularly important are selectivity and specificity of anticancer agents," Dr. Dan Dimitrijevich of nanoRANCH said in the release.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy